Adrenal Insufficiency Related Adverse Events in Congenital Adrenal Hyperplasia

Ali SR¹, Daniel E², Bryce J¹, Ikiroma A¹, Lewsey J³, Krone R⁴, Acerini C⁵, Krone N⁶, Das U⁷, Tomlinson J⁸, Korbonits M⁹, Higham C¹⁰, Darendeliler F¹¹, Guran T¹², Guven A¹³, Attapatu N¹⁴, Milenkovic T¹⁵, Raducanu-Lichiardopol C¹⁶, Hannema S¹⁷, Claahsen H¹⁸, Finken M¹⁹, Baronio F²⁰, Balsamo A²⁰, Einaudi S²¹, de Vries L²², Luczay A²³, Neumann U²⁴, Blankenstein O²⁴, Mohnike K²⁵, Bonfig W²⁶, Elsedfy H²⁷, Birkebaek N²⁸, Iotova V²⁹, Bachega T³⁰, Mendonca B³⁰, Correa Costa E³¹, Guaragna-Filho G³², Rey R³³, Cools M³⁴, Ross RJM², Ahmed SF¹

¹Developmental Endocrinology Research Group, University of Glasgow. ²Dept. Oncology & Metabolism, University of Glasgow. ⁴Institute of Metabolism & Systems Research, University of Birmingham. ⁵Dept. of Paediatrics, University of Cambridge. ⁶University of Sheffield. ⁷Alder Hey Childrens Hospital, Liverpool. ⁸Dept. of Endocrinology, William Harvey Research Institute, London. ¹⁰Dept. of Endocrinology, Manchester. ¹¹Istanbul Faculty of Medicine, Turkey. ¹²Marmara University, Dept. of Pediatric Endocrinology & Diabetes, Turkey. ¹⁴The Central Hospital, Columbo. ¹⁵University of Belgrade. ¹⁶University of Medicine & Pharmacy. ¹⁷Leiden University Medical Centre, Netherlands. ¹⁸Radboudumc Amalia Children's Hospital, Nijmegen. ²¹Torino -Regina Margherita Children's Hospital. ²²The Jesse Z & Sara Lea Shafer Institute for Endocrinology & Diabetes, Petah Tikva. ²³Ist Dept. of Paediatrics, Semmelweis Universität, Budapest. ²⁴Charité Universitätsmedizin, Berlin. ²⁵Otto-von-Guericke Universität Magdeburg, Magdeburg. ²⁶Dept. of Pediatrics, Klinikum Wels-Grieskirchen, Wels. ²⁷Ain Shams University, Cairo. ²⁸Dept of Pediatrics, Aarhus University, Cairo. ²⁹Dept of Pediatrics, Aarhus University, Cairo. ²⁹Dept of Pediatrics, Aarhus University, Cairo. ²⁰Dept of Pediatrics, Aarhus University, de Clínicas de Porto Alegre. ³²Catholic University, Porto Alegre. ³⁴Centro de Investigaciones Endocrinológicas, Buenos Aires ³⁴Dept. of Paediatric Endocrinology, Ghent University Hospital.

BACKGROUND

Congenital adrenal hyperplasia (CAH) is a rare condition characterised by adrenal insufficiency (AI) and is associated with a life long risk of adrenal crises, a leading cause of mortality in CAH.

There is a paucity of information on the epidemiology of acute adverse events (adrenal crises and sick day

RESULTS

• The median number of SDE for all centres per patient per year was 3.0 (IQR 1.7-4.7) for children and 3.9 (1.8-10.2) for adults (P=0.26)





episodes) in this population.

OBJECTIVE

investigate aetiology the frequency, То and consequences of adverse events secondary to AI in CAH

METHOD

A longitudinal analysis of 261 patients with CAH in the International Congenital Adrenal Hyperplasia Registry registry, www.i-cah.org) which (I-CAH collects information on acute adverse events.

RESULTS

Figure 1. CAH patients and diagnostic categories

1202 CAH patients in I-CAH Registry



Children had longer sick day episodes compared with adults (3 days (IQR 2.0-5.0) versus 2 days (1.0-3.0), P<0.05 and infectious illness was the most frequent precipitating event (Figure 3).

Figure 3. Precipitating events associated with sick days and adrenal crises Children Adults





- Data for 261 patients with 1 or more sick day episodes (SDE) was divided into paediatrics, age <18y (n=215) and adults, age \geq 18y (n=46)
- 1,034 SDE were evaluated. Of these, 920 SDE (608)

- In children, younger age and a low hydrocortisone (HC) dose were associated with a greater number of SDE (P<0.01)
- An adrenal crisis (AC) was reported in 4% (37/920) and 30% (34/114) of SDEs (Figure 4) in children and adults, respectively (P<0.05)

Figure 4. Adrenal crises



visits) were documented in children and 226 SDE (76 visits) in adults.

Table 1. Classification of 21-OHD phenotype in children and adults

Patients aged <18y, n (%)	Patients aged ≥18y, n (%)
211 (98.1%)	44 (95.6%)
198 (93.8%)	40 (90.9%)
13 (6.2%)	0
0	4 (9.1%)
	Patients aged <18y, n (%) 211 (98.1%) 198 (93.8%) 13 (6.2%)

*SW, salt-wasting; SV, simple-virilising; NC, non-classic CAH

• In children and adults, female sex was a predictor of hospital admission, P<0.05

CONCLUSIONS

- The I-CAH registry is a valuable tool for evaluating adverse events in patients with CAH.
- Preliminary data suggest that patients experience frequent SDE
- Young children on lower HC doses present with a greater number and longer duration of SDE
- Adults are more likely to experience AC.

Funding- SRA is funded by an unrestricted education award from Diurnal and the Gardiner Lectureship at the University of Glasgow.







